Llwytho...
Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
BACKGROUND: Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized controlled trials (RCTs) of exon skipping drugs h...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Orphanet J Rare Dis |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003096/ https://ncbi.nlm.nih.gov/pubmed/29907124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-018-0834-2 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|